文拉法辛与舍曲林治疗抑郁症对照研究

目的：比较文拉法辛与舍曲林治疗抑郁症的临床疗效和安全性。方法：将76例抑郁症患者随机分为文拉法辛组（38例）和舍曲林组（38例）,疗程6周。采用汉密尔顿抑郁量表17项（HAMD）评定疗效,治疗中出现的症状量表（TESS）评定不良反应和安全性。结果：文拉法辛组治疗1周起效;疗程结束时,两组疗效和HAMD评分差异无显著性,不良反应少而轻。结论：文拉法辛与舍曲林治疗抑郁症疗效相似,文拉法辛起效较快。     

帕罗西汀、文拉法辛、阿米替林对首发抑郁症认知功能的影响

目的 探讨帕罗西汀、文拉法辛、阿米替林对首发抑郁症认知功能的影响.方法 选择在我院住院的首发抑郁症患者120例,随机分为三组:A组、B组、C组,分别给予帕罗西汀、文拉法辛、阿米替林治疗,在治疗前、治疗8周末、随访1年末,采用数字划销测验(NCT)、修订韦氏成人记忆量表(WMS-RC)、威斯康星卡片分类测验(WCST)进行注意力、记忆功能、执行功能测定.结果 治疗前、治疗8周和随访1年后RAMD总分差异无显著意义(P＞0.05);治疗8周、1年时TESS评分,A组与B组差异无显著意义(P>0.05),A组与C组、B组与C组之间差异有显著意义(P<0.05);治疗8周、1年时与治疗前比较,三组NCT中的净分、失误率及WMS-RC的记忆商数均改善(P< 0.05),WCST的总刚验次数、持续错误数、随机错误数均下降(P<0.05);治疗8周、1年时净分、失误率、WMS-RC的记忆商数、WCST的总测验次数、持续错误数、随机错误数三组之间的差异均有显著意义(均P<0.05),但A组与B组之间差异无显著意义(P>0.05):1年时,三组的失误率下降值、记忆商增加值、净分增加值、总测验次数下降值、持续错误数下降值、随机错误数下降值均与HAMD减分值呈正相关(P<0.05),与TESS评分呈负相关(P＜0.05).结论 帕罗西汀、文拉法辛、阿米替林均可以改善抑郁症的认知功能,但阿米替林的抗胆碱能作用明显影响了认知功能改善程度.     

文拉法辛与舍曲林治疗强迫症的对照研究

目的比较文拉法辛与舍曲林治疗强迫症的疗效及不良反应。方法将符合CCMD-3强迫症诊断标准的72例患者随机分为两组,分别给予文拉法辛与舍曲林治疗8周。采用Yale-Brown强迫量表、汉密尔顿抑郁量表（HAMD）、汉密尔顿抑郁量表（HAMD）、汉密尔顿焦虑量表（HAMA）、不良反应量表（TESS）和临床疗效评定标准评定疗效和不良反应。结果文拉法辛与舍曲林疗效相当,两组显效率及有效率比较无显著性差异,两组不良反应发生率及其严重程度亦无显著性差异。结论文拉法辛治疗强迫症有较好的疗效,且不良反应轻微。     

文拉法辛与氟西汀治疗首发抑郁症对认知功能影响的对照研究

目的比较文拉法辛缓释剂与盐酸氟西汀对首发抑郁症患者认知功能的影响。方法80例首发抑郁患者接受12周文拉法辛缓释剂(A组,n=40)或盐酸氟西汀(B组,n=40)治疗。治疗前和治疗12周末采用17项汉密顿抑郁量表(HAMD17)和汉密顿焦虑量表(HAMA)评定疾病严重程度,韦氏记忆量表(WMSRC)、韦氏成人智力量表(WAISRC)、威斯康星卡片分类测验(WCST)评定患者神经心理学测验成绩,采用NicoletSpiritCA-1000型脑诱发电位仪对2个治疗组和正常对照组进行认知电位P300测试。结果①经配对t检验,治疗后A组和B组的记忆商数、长时记忆、短时记忆、瞬间记忆、语言智商、作业智商、智商均比治疗前明显改善(P<0.05或P<0.01),A组的WCST总数和持续错误数明显减少(P<0.05);A组P300波幅明显提高(P<0.05),B组P300潜伏期明显缩短(P<0.05)。②经OnewayANOVA检验,治疗前与对照组(n=36)比较,2组患者P300潜伏期均显著性延迟,P300波幅显著降低(P<0.05)。治疗后A组P300潜伏期和波幅与对照组无统计学差异(P>0.05),B组P300波幅仍显著低于对照组(P<0.05)。③经方差分析,治疗后A组重度患者(n=22)的HAMD17总分、睡眠分、HAMA总分、精神焦虑分均显著低于B组(n=29)(P<0.05或P<0.01);短时记忆分和操作智商均显著高于B组(P<0.05),WCST总数低于B组(P<0.05);治疗后A组重度患者(n=17)P300波幅显著高于B组重度患者(n=23)(P<0.05)。④经多元逐步回归分析,重度患者的记忆商数变化和短时记忆分变化均与睡眠分变化呈负相关(P<0.05或P<0.01),操作智商变化和智商变化均与药物治疗组呈负相关(P<0.05),P300波幅的变化与HAMA精神焦虑分改变呈负相关(P<0.01)。中度患者的语言智商变化与HAMA躯体焦虑分变化呈负相关(P<0.01),WCST分类数变化与HAMD17睡眠分变化呈正相关(P<0.05),P300潜伏期变化与HAMD17睡眠分变化呈正相关(P<0.05)。结论文拉法辛缓释剂和盐酸氟西汀治疗首发抑郁症均能改善患者的认知功能,文拉法辛缓释剂缓解重度抑郁症患者的临床症状、改善神经心理学成绩和提高P300波幅的作用比氟西汀明显。     

文拉法辛与米安色林治疗抑郁症的疗效对照分析

文拉法辛与米安色林（mianserin）均为新型抗抑郁剂。我们对两者的疗效及安全性进行了对照分析。现报告如下：     

舍曲林与帕罗西汀治疗抑郁症首次发病患者认知功能的相关研究

目的 比较舍曲林与帕罗西汀对抑郁症首次发病患者认知功能的影响及其相关因素.方法 将符合国际疾病分类第10版关于抑郁发作诊断标准、17项汉密尔顿抑郁量表(HAMD17)评分≥17分、年龄18～65岁的100例首次发病的门诊患者,按照随机数字表法分为舍曲林组(51例,剂量范围25～150 mg/d)和帕罗西汀组(49例,剂...     

文拉法辛治疗精神分裂症患者认知功能障碍的疗效

目的：探讨文拉法辛对精神分裂症患者认知功能障碍的治疗作用。方法：对43例达到显著进步以上的精神分裂症患者,随机分为文拉法辛组(22例)和对照组(2l例)分别给予文拉法辛和安慰剂治疗6周。采用韦氏成人智力量表(WAIS)、韦氏记忆量表(WMS)、威斯康星卡片分类测验(WCST)及副反应量表(TESS)进行评分。结果：治疗后以文拉法辛组认知功能改善显著较好。结论：文拉法辛对改善精神分裂症患者的认知功能障碍有益。     

舍曲林治疗阿尔茨海默病伴抑郁症状患者对认知功能的影响

目的探讨舍曲林治疗伴抑郁症状的阿尔茨海默病(AD)对其认知功能的影响。方法随机将66例伴抑郁症状的AD患者分为对照组及观察组,每组33例。对照组接受阿米替林治疗,观察组接受舍曲林治疗。对比2组临床疗效及认知功能变化情况。结果治疗前2组汉密尔顿抑郁量表(HAMD)及简易智力状态检查量表(MMSE)评分比较差异均无统计学意义(P0.05),治疗后4周,观察组HAMD评分及MMSE评分改善均明显优于对照组(P0.05)。对照组药物不良反应发生率为18.18%,观察组为27.27%,2组比较差异无统计学意义(P0.05)。结论舍曲林可有效改善伴抑郁症状的阿尔茨海默病患者的认知功能。     

文拉法辛联合阿立哌唑治疗难治性抑郁症的临床疗效及对认知功能的影响

目的 探讨文拉法辛联合阿立哌唑治疗难治性抑郁症的临床疗效及对认知功能的影响.方法 将128例难治性抑郁症患者随机分为对照组与观察组,对照组患者给予文拉法辛口服,观察组给予文拉法辛联合阿立哌唑治疗,疗程8周.比较2组临床疗效、认知功能及药物不良反应的差别.结果 治疗8周后观察组汉密尔顿抑郁量表（HAMD）各项评分显著低于对照组（P〈0.05）;观察组认知功能威斯康星卡片分类测验（WCST）正确反应数及完成分类数评分显著优于对照组（P〈0.05）;2组不良反应无显著差别（P〈0.05）.结论 文拉法辛联合阿立哌唑治疗难治性抑郁症可显著提高临床疗效、改善认知功能,且不增加不良反应.     

文拉法辛与阿米替林治疗抑郁症对照研究

为了解文拉法辛（商品名：博乐欣）与阿米替林治疗抑郁症的疗效和不良反应,我们对此进行了对照研究,现将结果报告如下。     

Sertraline treatment of elderly patients with depression and cognitive impairment

BACKGROUND: There is little information on the efficacy and side effects of antidepressant treatment in elderly patients with combined depression and cognitive impairment without dementia (DEP-MCI), and it is unclear if cognitive performance improves with antidepressant response in these patients. METHODS: In 39 elderly DEP-MCI patients, changes in depression and cognitive impairment were evaluated with open sertraline treatment up to 200 mg/day for 12 weeks. RESULTS: Of the 26 completers, 17 were responders and nine were non-responders. Diagnostic subtype of depression was unrelated to response. ANCOVA on WAIS-R digit symbol percent change scores revealed a significant effect for responder status (F = 5.59, p < 0.03), and age (F = 0.24, p < 0.64) and education (F = 1.64, p < 0.22) were not significant covariates. From pre-trial to post-trial, responders improved in WAIS-R digit symbol percent change scores (Mean -10% SD 24) while non-responders declined (Mean 14% SD 18; t = 2.60, p < 0.02). Other neuropsychological measures were unrelated to response. Percent change in HRSD scores showed significant inverse correlations with percent change in several cognitive measures. CONCLUSIONS: DEP-MCI patients showed moderate clinical response to sertraline treatment. When responders were compared to non-responders, cognitive improvement was limited to one measure of attention and executive function. Overall, there was little cognitive improvement with antidepressant treatment. The findings indirectly suggest that lack of improvement in cognition following treatment of depression in DEP-MCI patients may be associated with increased risk of meeting diagnostic criteria for dementia during follow-up.     

Venlafaxine in the treatment of postpartum depression

BACKGROUND: Although postpartum depression is a highly prevalent illness, antidepressant treatment studies of postpartum depression are sparse. Incomplete recognition and treatment of puerperal illness place women at risk for chronic depression and may have adverse effects on child development. METHOD: An 8-week, flexible-dose, open study of venlafaxine (immediate release; mean dose = 162.5 mg/day) was performed in a group of 15 women who met DSM-III-R criteria for major depressive disorder with onset within the first 3 months postpartum. Patients were assessed at baseline and every 2 weeks across the study. Measurements of outcome included the 17-item Hamilton Rating Scale for Depression (HAM-D), the Kellner Symptom Questionnaire, and the Clinical Global Impressions scale (CGI). RESULTS: Despite baseline scores of depression that were particularly high, response to treatment was robust. Twelve of 15 patients experienced remission of major depression (HAM-D score < or = 7 or CGI score < or = 2). Dramatic decrease in anxiety paralleled the decrease in depression across the sample. CONCLUSION: Venlafaxine is effective in the treatment of postpartum major depression. Early identification of women who suffer from postpartum mood disturbance is critical to minimize the morbidity associated with untreated mood disturbance and the effect of depression on children and families.     

强化心理治疗联合万拉法新对卒中后抑郁患者神经缺损的影响

目的 探讨强化心理治疗联合万拉法新对急性卒中后抑郁患者神经缺损的影响.方法 将126例急性脑卒中后并发早发性抑郁症患者按入选顺序随机分为对照组、万拉法新组和强化心理治疗+万拉法新组(联合治疗组),每组各42例.在治疗前,治疗4周、6周及90 d随访时对各组患者分别采用汉密尔顿(HAMD)抑郁量表、美国国立卫生研究院卒中(NIHSS)量表及Barthel指数量表进行疗效评价.结果 治疗前3组患者NIHSS评分及Barthel指数评分差异无统计学意义(P>0.05),治疗4周、6周及90 d随访时联合治疗组HAMD评分、NIHSS评分及Barthel指数评分较对照组、万拉法新组明显改善,差异均有统计学意义(P<0.05).结论 强化心理治疗作为抗抑郁药物治疗的辅助措施能显著增加卒中后抑郁患者的康复机会,疗效也更持久和稳定,能明显提高卒中患者的生活质量.

Abstract：

Objective To evaluate the effect of Venlafaxine plus psychotherapy on neurologic defect of patients with post-stroke depression (PSD). Methods One hundred and twenty-six patients with PSD were equally randomized into control group (treating with ordinary medicine and rehabilitation), Venlafaxine treatment group (ordinary treatment combined with venlafaxine) and therapeutic alliance group (ordinary treatment combined with venlafaxine and psychotherapy). The Hamilton Depression Rating Scale (HAMD), Barthel index (BI) and NIHSS were employed to evaluate the treatment efficacy before the treatment, 4 and 6 week and 90 d after the treatment. Results No significant differences in NIHSS scores and Brothel indexes among the 3 groups were noted before the treatment (P>0.05). Four and 6 week and 90 d after the treatment, the HAMD scores, NIHSS scores and Barthel indexes in the therapeutic alliance group improved significantly as compared with those in control group and Venlafaxine treatment group (P<0.05). Conclusion Strengthening psychotherapy, as an assistant measure of anti-depression drug therapy, can obviously increase the rehabilitation patents'chances and heal efficacy. It is lasting, stable, and worth to popularizing, and can improve the life quality of stroke patients.     

强化心理治疗联合万拉法新对卒中后抑郁患者神经缺损的影响

目的 探讨强化心理治疗联合万拉法新对急性卒中后抑郁患者神经缺损的影响.方法 将126例急性脑卒中后并发早发性抑郁症患者按入选顺序随机分为对照组、万拉法新组和强化心理治疗+万拉法新组(联合治疗组),每组各42例.在治疗前,治疗4周、6周及90 d随访时对各组患者分别采用汉密尔顿(HAMD)抑郁量表、美国国立卫生研究院卒中(NIHSS)量表及Barthel指数量表进行疗效评价.结果 治疗前3组患者NIHSS评分及Barthel指数评分差异无统计学意义(P>0.05),治疗4周、6周及90 d随访时联合治疗组HAMD评分、NIHSS评分及Barthel指数评分较对照组、万拉法新组明显改善,差异均有统计学意义(P<0.05).结论 强化心理治疗作为抗抑郁药物治疗的辅助措施能显著增加卒中后抑郁患者的康复机会,疗效也更持久和稳定,能明显提高卒中患者的生活质量.     

强化心理治疗联合万拉法新对卒中后抑郁患者神经缺损的影响

目的 探讨强化心理治疗联合万拉法新对急性卒中后抑郁患者神经缺损的影响.方法 将126例急性脑卒中后并发早发性抑郁症患者按入选顺序随机分为对照组、万拉法新组和强化心理治疗+万拉法新组(联合治疗组),每组各42例.在治疗前,治疗4周、6周及90 d随访时对各组患者分别采用汉密尔顿(HAMD)抑郁量表、美国国立卫生研究院卒中(NIHSS)量表及Barthel指数量表进行疗效评价.结果 治疗前3组患者NIHSS评分及Barthel指数评分差异无统计学意义(P>0.05),治疗4周、6周及90 d随访时联合治疗组HAMD评分、NIHSS评分及Barthel指数评分较对照组、万拉法新组明显改善,差异均有统计学意义(P<0.05).结论 强化心理治疗作为抗抑郁药物治疗的辅助措施能显著增加卒中后抑郁患者的康复机会,疗效也更持久和稳定,能明显提高卒中患者的生活质量.     

Sertraline as monotherapy in the treatment of psychotic and nonpsychotic depression

BACKGROUND: Previous studies suggest that selective serotonin reuptake inhibitors (SSRIs) are effective when used alone in the treatment of unipolar depression with psychotic features. The purpose of the present study was to examine the response to sertraline for patients with and without psychotic features using standard criteria such as recovery and remission. METHOD: An 8-week open-label trial of sertraline in depressed inpatients was conducted. Twenty-five subjects had DSM-IV major depressive disorder with psychotic features, and 25 had DSM-IV major depressive disorder without psychotic features. After a 1-week open washout, all subjects were rated using the Hamilton Rating Scale for Depression (HAM-D) and Brief Psychiatric Rating Scale (BPRS) at baseline. The HAM-D was administered weekly, and the BPRS was administered again only at the end of the 8-week trial. Medication dosage was started at 50 mg/day, increased to 100 mg/day after 1 week, and then increased up to 200 mg/day if subjects had not remitted. RESULTS: Depressed patients without psychosis responded significantly better than did depressed patients with psychosis using the criteria of remission (HAM-D score - 7; p =.001), response (HAM-D score - 50% of baseline score; p =.011), referral for electroconvulsive therapy (HAM-D score >/= 15; p =.011), or change in HAM-D scores (p =.016). Baseline HAM-D score and psychosis independently predicted response, whereas baseline BPRS scores did not, regardless of whether psychotic status was entered into the analyses. CONCLUSION: Psychotic depression responds more poorly than depression without psychosis to sertraline alone. Psychosis was a predictor of response independent of degree of depression and general psychopathology. Limitations due to an open-label design are discussed, as are differences between this study and others using SSRIs for psychotic depression.     

Venlafaxine in the treatment of depressive and vasomotor symptoms in women with perimenopausal depression

Perimenopause is often marked by vasomotor symptoms and dysphoria. Antidepressant studies have demonstrated decreased frequency and severity of hot flashes in breast cancer survivors and menopausal women. We hypothesized that venlafaxine would relieve both depressive and vasomotor symptoms in depressed perimenopausal women. Sixteen women fulfilling clinical criteria for climacteric phase and Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV criteria for a depressive episode were enrolled in an open-label 8-week trial of extended-release venlafaxine. Depressive and climacteric symptoms were monitored using the Hamilton Rating Scales for Depression (Ham-D) and Anxiety (Ham-A), Clinical Global Impression (CGI) scale, and Greene Climacteric Scale (GCS). Serum follicular stimulating hormone (FSH) and estradiol concentrations were monitored. Significant decreases in Ham-D and Ham-A scores and the GCS psychiatric subscale were seen after 2 weeks of treatment. In an intention-to-treat analysis, 81% of the subjects demonstrated a therapeutic antidepressant response (>50% decline in Ham-D score) and 75% achieved clinical remission (Ham-D score < or =7) after 8 weeks of venlafaxine therapy (75-225 mg/day). Total GCS scores declined 60%, and GCS vasomotor subscores decreased among those with vasomotor symptoms at baseline. These data suggest that venlafaxine treatment improves overall well-being, reduces depressive symptoms, and may diminish baseline vasomotor symptoms in depressed perimenopausal women. Further studies are warranted to investigate the utility of venlafaxine in perimenopausal depression.     

文拉法辛和帕罗西汀对伴发焦虑的女性抑郁症患者的疗效

目的 比较文拉法辛和帕罗西汀治疗伴发焦虑的女性抑郁症患者的效果.方法 将2018年2月～2020年2月收治的80例伴发焦虑的女性抑郁症患者作为研究对象,随机分组,对照组40例患者用帕罗西汀治疗,观察组40例患者用文拉法辛治疗,比较治疗前后两组患者的焦虑自评量表(SAS)评分、抑郁自评量表(SDS)评分、生活质量评分、睡...